Benzinga | Jul 7, 2021 08:37AM EDT

Xenon Pharmaceuticals Announces Completion Of Patient Randomization In XEN1101 Phase 2b 'X-TOLE' Clinical Trial, Announces Upcoming Investor Webinar

Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today provided an update on its ongoing XEN1101 Phase 2b "X-TOLE" clinical trial, announcing that randomization of 326 patients was completed in late June. Based on completion of patient randomization, Xenon anticipates topline results from the Phase 2b X-TOLE clinical trial in late September to mid-October 2021.

Mr. Ian Mortimer, Xenon's President and Chief Executive Officer, said, "We are pleased to announce that patient randomization in our XEN1101 Phase 2b "X-TOLE" clinical trial is complete. Given the strong screening at the end of the recruitment period, we randomized more patients than the 300 originally planned, and we look forward to topline data in late September to mid-October. In advance of these results, we have invited two leading key opinion leaders in the epilepsy space -- Dr. Jacqueline French and Dr. Michael Rogawski -- to join us for a webinar to discuss XEN1101, the X-TOLE clinical trial, and the broader focal epilepsy landscape."

Webinar Event: "A Discussion of XEN1101 and the Focal Epilepsy Landscape"Date: Monday, July 12, 2021Time: 10 am-12 pm Eastern Time (7 am-9 am Pacific Time)Registration: Participants may register on the Investors section of Xenon's website.

Speakers on the July 12th webinar include:



* Dr. Jacqueline French, Professor of Neurology in the Comprehensive Epilepsy Center at NYU Langone School of Medicine and Founder/Director of the Epilepsy Study Consortium

* Dr. Michael Rogawski, Professor in the Department of Neurology with joint appointment in the Department of Pharmacology, and an affiliate member of the Center for Neuroscience at the University of California, Davis

* Ian Mortimer, President and CEO, Xenon Pharmaceuticals

* Dr. Simon Pimstone, Executive Chair of the Board, Xenon Pharmaceuticals

* Dr. Chris Von Seggern, Chief Commercial Officer, Xenon Pharmaceuticals

The webcast will be broadcast live on the Investors section of the Xenon website, and participants will be able to submit text questions via the webcast portal. The webinar will also be available for replay following the event.